Drugs / SB15
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04450329 | Jun 2020 → Apr 2021 | wet macular degeneration | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04450329 ↗ |
| Route | Intravitreal | “via intravitreal injection” NCT04450329 ↗ |